Introduction:
As the survival of patients with primary coronary events continues to increase, the number of patients presenting with coronary artery disease unsuitable to further revascularization techniques and symptoms refractory to medical therapy also continues to rise. Side by side, As a consequence of the worldwide increase in life expectancy, and due to improvements in the treatment of heart failure in recent years, the proportion of patients that reach an advanced phase of the disease, so-called end stage, refractory or terminal heart failure, is steadily growing.1 Treatment options for these end-stage heart diseases are at present, limited to few modalities like stem-cell therapy and heart transplantation. Stem-cell therapy is promising but at present not in routine use. On the other hand, heart transplantation is seriously limited by the scarcity of donated organs. So, quest for newer, versatile and effective treatment modality is going on relentlessly. And to this effort, extra-corporeal shock-wave therapy may add to the armamentarium of mankind in the battle against the deadly disease in future.

Basic concepts:
Three types of acoustic waves are mainly used in the medical field, extracorporeal shock waves, pressure waves and ultrasound. Shock waves are three-dimensional acoustic waves characterized by high amplitudes and abrupt peaking of 35 to 120 MPa that propagates rapidly through a medium.2,3 They arise from sharp and violent disturbances generated from a lightning stroke, bomb blast, or other form of intense explosion. Many of the physical effects depend upon the energy involved, measured in millijoules (mJ).4 For medical use, shock waves are concentrated into small focal areas of 2 to 8 mm in diameter in order to optimize the therapeutic effects and to minimize the effects on other tissues.5

Abstract:
Management of end-stage coronary artery disease is often hopeless because of lack of evidence-based, uniformly effective, safe, and inexpensive treatment options. Gene- or stem-cell-based therapies are not yet ready for routine clinical use, and heart transplantation is seriously limited by the scarcity of organs. In this regard, extracorporeal shockwave therapy is emerging as a noninvasive means to treat refractory angina and heart failure. Shockwaves are a form of acoustic wave having very high amplitude, abrupt peaking and very short duration, capable of inducing neovascularization. A number of preclinical and clinical studies are in favour of its efficacy and safety. However, more robust evidence is needed before routine application is recommended. Larger, randomized, placebo-controlled trials will hopefully define its status in the armamentarium of mankind in the battle against the deadly disease in future.

(Cardiovasc. j. 2011; 4(1): 80-87)

Address of Correspondence: Dr. AKM Monwarul Islam, Department of Cardiology, National Institute of Cardiovascular Diseases, Dhaka, Bangladesh. Email: drmonwarbd@yahoo.com
In spite of being sound waves, ultrasound and shockwaves are not same. Therapeutic ultrasound has lower level of energy (<0.5 MPa), is diffuse, reflected by ribs and mainly acts by producing heat within the tissues. On the other hand, cardiac shockwaves have higher level of energy (~10 MPa), are more focused, not reflected by ribs and mainly acts by producing mechanical effects.2,8

Medical Application of Shockwave:
Shockwaves are being used for more than two decades in urology, to breakdown renal stones (extra-corporeal shock-wave lithotripsy). It is also used to disintegrate gall stones. Orthopedic applications include treatment of planter fasciitis, epicondylitis, calcaneal spur, non-union, etc.9,10 For treatment of stones, high-energy (e.g. 900 Bars i.e. 90 MPa) shockwaves are used. On the other hand, low-energy, i.e. nearly one-tenth the energy of urological application (100 Bars i.e.10 MPa) is needed for cardiovascular conditions.8 Recently, shockwaves have been used to treat refractory skin ulcers11-12, erectile dysfunction13 and chronic pelvic pain syndrome14.
Methods of Application of Cardiac Shockwave Therapy:
For clinical application, shockwaves are generated by electro-hydraulic effect. High voltage creates electric spark discharge. The water vaporizes and creates an explosion, generating high-energy shock-waves. Now the shockwaves are delivered non-invasively to the affected ischaemic area across the skin. Echocardiography is used to locate the area of interest, and to map the exact position and extent of ischaemic zone. Shockwaves are then delivered via the anatomical acoustic window to the treatment area under ECG-R wave gating to avoid ventricular arrhythmias. Several treatment sessions are required.

Studies Related to Cardiac Shockwave Therapy
Shockwaves have chiefly been studied in coronary artery disease and heart failure. A number of studies have been carried out in animals with encouraging results. However, most of the studies are relatively small, and not well-designed.

Refractory Angina Pectoris:
Effects of low-energy shockwaves have been observed in both animals and humans. Nishida et al. observed significant up-regulation of mRNA expression of VEGF and its receptor Flt-1 in cultured human umbilical vein endothelial cells treated with SW. Subsequently, a porcine model of chronic myocardial ischemia was made by placing an ameroid constrictor at the proximal segment of the left circumflex coronary artery, which gradually induced a total occlusion of the artery with sustained myocardial dysfunction but without myocardial infarction in 4 weeks. Thereafter, extracorporeal shockwave therapy to the ischemic myocardial region (200 shots/spot for 9 spots at 0.09 mJ/mm²) was performed (n=8), which induced a complete recovery of LVEF (51±2% to 62±2%, p<0.01), wall thickening fraction (13±3% to 30±3%, p<0.01), and regional myocardial blood flow (1.0±0.2 to 1.4±0.3 ml.min⁻¹.g⁻¹, p<0.01) of the ischemic region in 4 weeks, but not in control group.¹⁹

A human study was conducted by Fukumoto et al. which involved 9 patients with end-stage coronary artery disease with no indication of PCI or CABG. Extracorporeal shockwave therapy was applied to the patients (200 shots/spot at 0.09 mJ/mm² for 20–40 spots, 3 times a week/series), and were followed-up at 1, 3, 6, and 12 months after the therapy to examine the impact on myocardial ischemia. Canadian Cardiovascular Society (CCS) functional class score improved (from 2.7±0.2 to 1.8±0.2, p<0.01), nitroglycerin use decreased (from 5.4±2.5 to 0.3±0.3/week, p<0.05), and myocardial perfusion improved in dipyridamole stress thallium scintigraphy (severity score, 25.2±7.2% improvement, p<0.05; extent score, 23.3±9.0% improvement, p=0.10; washout rate, 20±3 to 34±3, p<0.05).²⁴

Refractory Heart Failure:
Studies have demonstrated symptomatic and objective improvement of cardiac function in heart failure. In a rodent model, left anterior descending artery was ligated to induce ischaemic heart failure (treatment group, n=60, control group, n=60). After 4 weeks, low-energy shock waves were applied over the epicardium in direct contact with the infarcted myocardium (300 impulses at 0.38 mJ/m²).
Histologic analysis revealed significant angiogenesis 6 weeks (treatment group: 8.2±3.7 vs. control group: 2.9±1.9 vessels/field, p=0.016) and 14 weeks (treatment group: 7.1±3.1 vs. control group: 3.2±1.8 vessels/field, p=0.011) after shockwave treatment. In the treatment group, ventricular function improved throughout the follow-up period after 6 weeks (37.4±6% vs. 39.5±9%, p<0.001) and 14 weeks (39.5±6% vs. 39.5±9%, p<0.001), but not in the control group. Rat brain natriuretic peptide levels were lower and vascular endothelial growth factor, Fms-related tyrosine kinase 1, and placental growth factor levels were higher after 1, 2 and 7 days in the treatment group.25

In a human study by Vasyuk et al.24 patients with ischemic heart failure and LVEF<40% received ECSW therapy in addition to their regular treatment. ECSW was performed in 9 sessions with 100 shocks per spot in viable segments, and the patients were evaluated at baseline and at 3 and 6 months. ESW significantly decreased NYHA class at 3 months (from 2.2±0.8 to 1.7±0.7, p<0.01) and 6 months (1.7±0.7, p<0.01). Six-minute walk test improved at 3 months (from 414±141 to 509±141, p<0.01) and at 6 months (to 538±116, p<0.01), CCS angina class decreased at 3 months (from 2.6±0.7 to 2.1±0.8, p<0.01) and at 6 months (to 1.9±0.7, p<0.01). A significant increase in LVEF at rest at 3 and 6 months after shockwave therapy (from 32.2±6.0 to 34.8±9.6 and 37.7±9.5, p=0.03, respectively) was noted. Summed rest score (from 23.9±8.1 to 21.4±7.1, p=0.03) and stress score improvement (from 28.2±8.4 to 24.6±6.4, p=0.04) by SPECT was registered.26

**Acute Myocardial Infarction:**
Effect of shockwave therapy on LV remodeling has been observed in animal models of AMI by Uwatoku et al.27 and Ito et al.28 Uwatoku et al. created AMI by surgical excision of proximal left circumflex coronary artery (n=20). In the early treatment protocol (n=5, shockwaves were started 3 days after AMI), LVEF was higher (42±1% vs. 32±1%, p<0.001) and left ventricular end-diastolic volume (LVEDV) was smaller (95±1 vs. 99±2 ml, p<0.05) in shockwave group compared with the control group (n=5). Furthermore, wall thickening fraction (32±1 vs. 28±1%, p=0.01), regional myocardial blood flow (1.7±0.2 vs. 1.0±0.1 ml/min/g, p<0.01), and number of capillaries in the border zone (134±15 vs. 93±34 mm², p=0.0001) were all significantly improved. By contrast, in the late treatment group (n=5, onset of therapy 4 weeks after AMI), no such beneficial effects of the shock wave therapy were noted. Recently, Ito et al. have demonstrated beneficial effects of SW therapy on LV remodeling in pigs. Pigs were subjected to a 90-min ischemia followed by reperfusion using a balloon catheter and were randomly assigned to two groups with or without SW therapy to the ischemic border zone (n=15 each). Four weeks after ischaemia-reperfusion, compared with the control group, the shockwave group showed significantly ameliorated LV remodeling in terms of LV enlargement (131±9 vs. 100±7 ml), reduced LVEF (28±2 vs. 36±3%), and elevated LVEDP (11±2 vs. 4±1 mmHg) (all p<0.05, n=8 each). The shockwave group also showed significantly increased regional myocardial blood flow (-0.06±0.11 vs. 0.36±0.13 ml/min/g, p<0.05), capillary density (1.233±31 vs. 1.560±60/mm², p<0.001), and endothelial nitric oxide synthase activity (0.24±0.03 vs. 0.41±0.05, p<0.05) in the ischemic border zone compared with the control group (n=7 each).

**Peripheral Arterial Disease:**
Shockwaves have been applied for 3 weeks to hind-limb ischaemia in a rabbit model induced by the surgical excision of unilateral femoral artery. There were improvement of blood flow, blood pressure and capillary density in the affected limb receiving ESW, but not in the control group (Oi et al. 2008).29 Two clinical trials with 12 patients of Fontaine stage II of peripheral arterial disease have recently been reported by Serizawa et al.30 The patients were treated with SW session consisted of 200 shots in each 40 spots in the ischemic calf muscle at 0.004–0.054 ml/mm². In the first trial, 6 patients with arteriosclerosis obliterans were treated with SW therapy 3 times per week in the first (day 1, 3, 5) and fifth weeks (day 29, 31, 33). The maximum walking distance at 4 and 8 weeks increased from baseline (0 week), but gradually decreased after 12 weeks. In the second trial, another 6 patients were treated (5 with arteriosclerosis obliterans and one with Buerger’s disease) with shockwave therapy 3 times per week for 3 consecutive weeks. In this second trial, maximum walking distance significantly increased at 4 weeks (166±6% from baseline, p=0.04), and the beneficial effect of shockwave therapy sustained at 8 weeks (153±5% from baseline, p=0.03) and 12 weeks (163±6% from baseline, p=0.02) and 24 weeks (156±12% from baseline, p=0.0X). No procedural complications or adverse effects were noted.
**Table-I**

*Studies related to cardiac shockwave therapy.*

<table>
<thead>
<tr>
<th>Study/Author(s)</th>
<th>Type</th>
<th>Sample size</th>
<th>Indication</th>
<th>Methods</th>
<th>Results</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nishida et al.¹⁹</td>
<td>Randomized, case-control study, in pigs</td>
<td>N=16; cases=8, controls=8</td>
<td>Chronic myocardial ischaemia induced by amerox constrictor in proximal LCX</td>
<td>200 shots/spot for 9 spots at 0.09 ml/mm²</td>
<td>Improvement of LVEF, wall thickening and regional MBF.</td>
<td>No complications observed.</td>
</tr>
<tr>
<td>Fukumoto et al.²⁴</td>
<td>Non-randomized study, in human</td>
<td>N=9; cases=9, no control</td>
<td>End-stage coronary artery disease with no indications for PCI or CABG</td>
<td>200 shots/spot at 0.09 ml/mm² for 20-40 spots, 3 times a week/series for 3 series; follow up for 12 months.</td>
<td>Positive effects on symptoms, nitroglycerine use, MBF by dipyridamole-stress scintigraphy.</td>
<td>No complications observed.</td>
</tr>
<tr>
<td>Zimpfer et al.²⁵</td>
<td>Randomized, case-control study, in rodents</td>
<td>Cases=60, controls=60, healthy controls=30.</td>
<td>Ischaemic heart failure was induced by ligation of LAD.</td>
<td>After 4 weeks of ligation, SW was applied directly over infarcted myocardium (300 impulses at 0.38 ml/m²); followed-up for 14 weeks.</td>
<td>Significantly increased angiogenesis, upregulation of growth factors, and decreased brain natriuretic peptide levels in cases, but not in controls.</td>
<td>No complications observed.</td>
</tr>
<tr>
<td>Vasyuk et al.²⁶</td>
<td>Non-randomized study, in human</td>
<td>N=24; cases=24, no control</td>
<td>Chronic ischaemic heart failure with LVEF 40%, no indications for PCI or CABG.</td>
<td>100 shots/spot at 0.09 ml/mm², 3 times a week/series for 3 series; follow up for 6 months.</td>
<td>Improvement of symptoms, six-minute walk test, MBF by SPECT.</td>
<td>No complications observed.</td>
</tr>
<tr>
<td>Uwatoku et al.²⁷</td>
<td>Randomized, case-control study, in pig</td>
<td>N=20; early treatment protocol cases=5, late treatment protocol cases=5, controls=5 in each group.</td>
<td>AMI created by surgical excision of LCX.</td>
<td>Early treatment protocol: SW therapy started 3 days after AMI; late treatment protocol: SW therapy started 4 weeks after AMI.</td>
<td>Significantly ↑LVEF, ↓LVEDV, ↑wall thickening, ↑number of capillaries in early treatment group. In late treatment group, no beneficial effects.</td>
<td></td>
</tr>
<tr>
<td>Ito et al.²⁸</td>
<td>Randomized, case-control study, in pig</td>
<td>N=30; cases=15, controls=15</td>
<td>AMI induced by inflation of a balloon catheter followed by reperfusion by deflating the balloon.</td>
<td>200 shots/spot at 0.09 ml/mm² for 9 spots/animal, 3 times in first week/series; follow up for 1 month.</td>
<td>Significant positive effects on LV remodeling in terms of LVIDD, LVEF and LVEDP. Significantly ↑MBF, capillary density and eNOS synthase activity.</td>
<td></td>
</tr>
<tr>
<td>Oi et al.²⁹</td>
<td>Randomize, case-control study, in rabbits.</td>
<td>N=18; cases=15, controls=15</td>
<td>Surgical excision of unilateral femoral artery.</td>
<td>200 shots/spot at 0.09 ml/mm² for 30 spots, 3 times in first week for 3 weeks; follow up for 1 month.</td>
<td>↑blood flow, blood pressure and capillary density in the affected limb.</td>
<td></td>
</tr>
<tr>
<td>Serizawa et al.³⁰</td>
<td>2 clinical trials with 12 patients in Fontaine stage II.</td>
<td>N=12; First trial= 6 patients, Second trial= 6 patients.</td>
<td>Fontaine stage II of peripheral arterial disease.</td>
<td>200 shots in 40 spots at 0.004–0.054 ml/mm². First trial: 3 times/ wk in week 1 &amp; 5. Second trial: 3 times/wk for 3 consecutive weeks.</td>
<td>First trial: MWD at 4 and 8 weeks increased, but gradually decreased after 12 weeks. Second trial: MWD significantly increased at 4 weeks.</td>
<td>No complications observed.</td>
</tr>
</tbody>
</table>
Limitations of Cardiac Shockwave Therapy:
The passage of shock waves to their target can result in damage to tissues. This may result in localized bleeding\textsuperscript{31,32}, and damage to lung parenchyma\textsuperscript{33}. Higher energy pulses, 0.5 mJ/mm\textsuperscript{2} or more, can facilitate free radical formation and cause ultrastructural changes in cytoplasm and mitochondria\textsuperscript{34-37}. Development of cardiac arrhythmias is another possibility. The pressure threshold for this appears to be in the range of 1 to 10 MPa\textsuperscript{38,39}. However, most of these complications were not observed with low-energy shock waves used in cardiovascular arena.

Current Status of Cardiac Shockwave Therapy:
From the available data, extracorporeal cardiac shock-wave therapy appears to have some role in managing end-stage cardiac diseases, specially where standard revascularization procedures are not indicated. However, this modality of treatment has not been recommended for cardiac disorders by the prestigious regulatory authorities around the world, including Food and Drug Administration (FDA) of USA, Medicines and Healthcare products Regulatory Agency (MHRA) of UK, European Medicines Agency (EMA) of European Union and Therapeutic Goods Administration (TGA) of Australia. Standard treatment guidelines on coronary artery disease and heart failure have not yet addressed this issue. At present, a number of clinical trials are going on to determine the efficacy, as well as, the safety of cardiac shock wave therapy in refractory angina\textsuperscript{40-43} and advanced heart failure\textsuperscript{44}. However, these studies are relatively small.

Future Directions:
Extracorporeal cardiac shock-wave therapy is a new, non-invasive treatment modality for a number of cardiovascular disorders, including refractory angina and end-stage heart failure, where other standard therapies can not be applied. Its indications are rapidly expanding. Among others, peripheral vascular disease and impotence are the emerging applications. It can probably be used as a hybrid procedure in combination with existing revascularization strategies i.e. PCI and CABG, as well as, with other emerging modalities like gene or stem-cell therapy. However, its efficacy and safety should be ascertained by larger, multi-centric, placebo-controlled clinical trials. The indications and contraindications should more precisely be defined. Standard guidelines for the treatment of coronary artery disease and heart failure should address this newer modality, before routine applications. Otherwise, chances of its inappropriate and potentially harmful use remain.

Conclusion:
Extracorporeal cardiac shockwave therapy has brought about a ray of hope to a growing cohort of people of end-stage heart disease. It appears to be effective and safe for clinical use. However, further larger, multi-centric, placebo-controlled clinical trials are needed before recommendation of its routine clinical use. The indications and contraindications should more precisely be defined. Standard guidelines for the treatment of coronary artery disease and heart failure should address this newer modality, and define its exact role in management of heart diseases. Otherwise, inappropriate and potentially harmful use is of concern.

Take-home Message:
Extra-corporeal cardiac shock-wave therapy is a newer, non-invasive treatment modality.

Shockwaves are sound waves of very high amplitude and short duration.

Low-energy shockwaves are suitable for cardiovascular applications.

Present indications include refractory angina and heart failure, where PCI and CABG are not indicated.

The principal therapeutic benefit appears to derive from angiogenesis.

Uniform indications, contraindications, and treatment protocol are yet to be developed.

Not yet approved by regulatory authorities for treating cardiovascular conditions.

Potential future applications include as a hybrid procedure with gene or cell therapy.

Conflict of Interest - None.

References:


